Smith Moore & CO. Has $1.21 Million Position in Pfizer Inc. (NYSE:PFE)

Smith Moore & CO. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 26.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,759 shares of the biopharmaceutical company’s stock after selling 16,476 shares during the period. Smith Moore & CO.’s holdings in Pfizer were worth $1,214,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Unison Advisors LLC raised its holdings in shares of Pfizer by 1.4% in the 4th quarter. Unison Advisors LLC now owns 88,978 shares of the biopharmaceutical company’s stock worth $2,361,000 after buying an additional 1,266 shares in the last quarter. Wescott Financial Advisory Group LLC grew its position in Pfizer by 5.6% in the fourth quarter. Wescott Financial Advisory Group LLC now owns 16,381 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 864 shares during the period. Foundry Partners LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $20,996,000. Huber Capital Management LLC lifted its holdings in Pfizer by 142.4% during the 4th quarter. Huber Capital Management LLC now owns 488,288 shares of the biopharmaceutical company’s stock valued at $12,954,000 after purchasing an additional 286,842 shares during the last quarter. Finally, Uniting Wealth Partners LLC acquired a new position in Pfizer in the fourth quarter valued at about $725,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 5.4 %

Shares of NYSE PFE opened at $22.99 on Friday. Pfizer Inc. has a fifty-two week low of $22.95 and a fifty-two week high of $31.54. The firm has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $25.87 and its 200 day simple moving average is $26.76.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company earned $0.10 EPS. The firm’s revenue was up 24.7% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.